C0678222||breast cancer
C1519691||tumor subtype
C1519691||tumor subtypes
C0238033||male breast cancer
C0238033||male breast cancer
C0007104||female breast cancer
C0007104||female breast cancer
C1709599||population-based study
C0238033||male breast cancer
C0007104||female breast cancer
C0242638||Surveillance, Epidemiology, and End Results (SEER) program
C1709599||population-based cohort study
C1519691||tumor subtype
C0678222||BC
C2603343||study
C0005680||black
C0001792||older
C1298736||histological grades
C0027651||tumors
C0024204||lymph node
C0027627||distant metastases
C1702024||human epidermal growth factor receptor 2
C1702024||human epidermal growth factor receptor 2
C0205160||negative
C0027651||tumors
C2348819||triple-negative
C2348819||triple-negative
C3898879||hormone receptor (HoR)-positive/HER2-positive
C2348819||triple-negative
C0449560||subtypes
C0238033||male breast cancer
C2348819||triple-negative
C0238033||male breast cancer
C1515021||HoR-positive/HER2-negative subgroup
C0243095||to die
C0678222||BC
C0936012||analysis
C0678222||BC
C0238033||male breast cancer
C0007104||female breast cancer
C2348819||triple-negative
C0449560||subtype
C1517331||further
C0220825||investigation